Biorestorative Therapies, Inc. · NASDAQ:BRTX
Biorestorative Therapies — Investor Presentation (May 2014)
26 slides from Biorestorative Therapies's investor presentation, May 29, 2014
Slide 1: BioRestorative Therapies: A Stem Cell Biotechnology Company
biorestoratlve BioRestorative Therapies: A Stem Cell Biotechnology Company biorestordtlve May 2014 ¢ OTC/BB: BRTX °¢ biorestorative.com a
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including statements concerning the ability of BioRestorative Therapies, Inc. (the “Company”) to develop its adult stem cell business, the future of regenerative medi
Slide 3: Corporate Overview
man Corporate Overview Second-Generation Stem Cell Regenerative Medicine Company BioRestorative Therapies (“BRT”) is a life sciences company focused on adult stem cell-based cellular therapies for various personal medical applications. BRT develops products and medical procedures using cell and tiss
Slide 4: Lead Therapeutic Program
gun Lead Therapeutic Program biorestordtlve
Slide 5: brtxDISC Overview
mae OrtxDISC™ Overview brtxDISC™ (Disc Implanted Stem Cells) Program Non-surgical autologous stem cell treatment for bulging and protruding disc disease Outpatient procedure performed in a physician’s office is intended for patients who have failed all non-surgical disc treatments and face surgery A
Slide 6: brtxDISC Target Markets
brtxDISC™ Target Markets Stenosis Protruding, Bulging Disc Disease biorestoratlve
Slide 7: brtxDISC Market Size & Costs
uum DItxDISC™ Market Size & Costs Annual brtxDISC™ Procedure Incidence Surgical Cost (Estimated Somneerer (U.S.) Cost) Spinal Fusion 300,000 $75-100K $18K $57-82K lee 200,000 $35-50K $18K $17-32K Replacement “p Discectomy 200,000 $20-50K $18K $2-32K Surgical procedures are typically followed by addi
Slide 8: Essential Proprietary Procedure
Essential Proprietary Procedure | Cell Culturing * Utilizes patient’s own stem cells to repair damaged tissue * Disc procedure requires the selection of mesenchymal stem cells that can survive in low oxygen (hypoxic) and avascular (lack of blood supply) environment Therapeutic Delivery Device + Esse
Slide 9: brtxDISC Cell Delivery Device
mun OFtxDISC™ Cell Delivery Device bi orestordilve
Slide 10: Delivery Device Animation
mum Delivery Device Animation digex 10 therapies
Slide 11: Short Physician Learning Curve
gan Short Physician Learning Curve Certain physicians already trained and skilled in performing disc injections 5 Groups Physiatrists Pain Management Physicians Interventional Radiologists Orthopedic Spine Physicians Neurosurgeons bi orestorave WO the ro pies
Slide 12: brtxDISC Process Overview
mum DItxDISC™ Process Overview Physician purchases collection/delivery device kit ia Patient receives cells via brtxDISC™ Delivery Device in physician’s office Physician collects patientcell sample BRT sends therapeutic cells/dose back to physician cells for lab culturing to BRT | Physician sends pa
Slide 13: brtxDISC MRI Results
brtxDISC™ MRI Results * 42y/o Male: Annulartear at L5-S1 noted on 2003 MRI and radiculopathy diagnosed. 2007 MRI showed a mild L5-S1 disc bulge. ¢ Treated in Physician’s Office: 5-month follow-up MRI showed complete resolution of the L5-S1 disc bulge on both sagittal and axial slices with some concu
Slide 14: brtxDISC Clinical Trial PI's
gue DItxDISC™ Clinical Trial Pl’s e Gregory E. Lutz, M.D — Physiatrist-in-Chief Emeritus for Hospital for Special Surgery (HSS) and is a member of the Board of Trustees — Regenerative Medicine clinical trial experience — Spine Device Company, principal — Associate Professor of Clinical Rehabilitatio
Slide 15: brtxDISC Clinical Trial
wee OFtxDISC™ Clinical Trial Safety and Preliminary Efficacy Study of Hypoxic Cultured Mesenchymal Stem Cells in Subjects with Lumbar Back Pain e Phase 2 -— Prospective, Controlled, Randomized, Double Blind Clinical Trial ¢ 100 Patients — Multicenter; 24-36 Month Study © Cost -- ~$35,000/patient ¢ P
Slide 16: brtxDISC Near Term Goals
mu OrtxDISC™ Near Term Goals 16 Finalize retrospective safety study of treated patients; submit results for publication (3Q 2014) Complete FDA-related work pertaining to the therapeutic delivery device (3Q 2014) Hold pre-trial meeting with FDA (4Q 2014) Finalize trial preparation and file IND/IDE wi
Slide 17: Brown Fat - Metabolic Program
Brown Fat - Metabolic Program Magnification of brown adipose derived stern cells cultured and differentiated inta brown adipacytes an porous extracellular matrix scaffolds ThermoStem® Program (Brown Fat Stem Cells) Potential Treatments for Type 2 Diabetes and Obesity biorestoratlve
Slide 18: ThermoStem — Brown Fat Program
ThermoStem — Brown Fat Program “One of the most powerful organs in the body....Since it consumes both glucose and fatty acids, it is possible we could utilize brown fat to treat obesity and metabolic dysfunction seen in diabetes and hyperlipidemia. ” - Aaron M. Cypress, M.D., Ph.D., Joslin Diabetes
Slide 19: Pfizer — BRT Collaboration
gan Pfizer — BRT Collaboration @@ pit J brt eBRT and Pfizer will jointly conduct a study entitled “Development and Validation of a Human Brown Adipose Cell Model” eFurther characterize the identity and metabolic function of these cell lines eAdvances Each Company’s Programs bi orestorave 19900 thera
Slide 20: Brown Fat Cells Implanted in a Biological Scaffold
| Brown Fat Cells Implanted in a Biological Scaffold Cell delivery method incorporates subcutaneous implant of decellularized scaffold containing brown fat 20 biorestordtlve
Slide 21: Publication in STEM CELLS
mau Publication in STEM CELLS STEM CELLS’ bi Ss 21
Slide 22: Preclinical — Glucose/Weight
mu Preclinical — Glucose/Weight Basal Blood Glucose Levels Body Weight 600 40 soo A B 30 400 * 3 § : £ = = 300 Ser $20 3 a. 200 10 100 5 ° ° 2203 4 5 6 7 8 9 1041 12 13 —eHcontral 10203 4 5 6 7 8 8 40 4112 13 ~eXcontral ‘Weeks after transplantation — Weeks after transplant ey Fig. 7. (A) Glucose lev
Slide 23: Preclinical — Trig/Chol Levels
mamas Preclinical — Trig/Chol Levels ™ Baseline @1Mth © 2Mth @3Mth = 4Mth Trig-ctrl mg/dL Trig—tx mg/dL Chol-ctrl mg/dL Chol-tx mg/dL Baseline 1Mth 2Mth 3Mth 4Mth Trig—ctrl mg/dt 115416 147413 159421 165414 18816 Trig — tx mg/d 120414 142415 13119 113411 114410 Chol— ctrl mg/dt 136416 1515615 188426
Slide 24: Highlights of Brown Fat Program
gaa Highlights of Brown Fat Program Treatment design is an allogeneic cell based therapy — faster to market with limited competition Well conceived delivery method — subcutaneous injection of a biodegradable, biological scaffold to allow brown fat tissue to remain where transplanted and to continue
Slide 25: Spinal disc program is poised to enter Clinical Trials
Spinal disc program is poised to enter Clinical Trials — IRBapproval secured — Retrospective human safety/feasibility study underway Proprietary therapeutic disc delivery device offers additional opportunities for value creation Metabolic Platform (Brown Fat) Program addresses large markets — Develo
Slide 26: Thank You
Ne) estoratlve Thank You >restort May 2014 * OTC/BB: BRTX ° biorestorative.com va
BioRestorative Therapies — Investor Presentation (May 2014) on 6ix